Genvoya and Bone density abnormal - a phase IV clinical study of FDA data

Summary:

Bone density abnormal is reported as a side effect among people who take Genvoya (cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate), especially for people who are male, 50-59 old, have been taking the drug for 5 - 10 years also take Truvada, and have Hepatitis b.

The phase IV clinical study analyzes which people have Bone density abnormal when taking Genvoya. It is created by eHealthMe based on reports of 13,480 people who have side effects when taking Genvoya from the FDA, and is updated regularly.

What is Genvoya?

Genvoya has active ingredients of cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. It is often used in hiv infection. eHealthMe is studying from 13,538 Genvoya users. Check the latest studies of Genvoya.

What is Bone density abnormal?

Bone density abnormal is found to be associated with 247 drugs and 252 conditions by eHealthMe. Check the latest studies of Bone density abnormal.

On May, 21, 2026

13,480 people reported to have side effects when taking Genvoya.
Among them, 395 people (2.93%) have Bone density abnormal.

Could Genvoya cause Bone density abnormal?

Among these 395 people:

How long have people been on Genvoya when they have Bone density abnormal? *

Click here to view more results

What is the gender of people who have Bone density abnormal when taking Genvoya? *

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Genvoya and have Bone density abnormal?

- Check whether Bone density abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Genvoya:

Genvoya (13,538 reports)

Bone density abnormal treatments and more:

Bone density abnormal (7,126 reports)

How severe was Bone density abnormal and when was it recovered:

Bone density abnormal in Genvoya

Expand to all the drugs that have ingredients of cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate:

Bone density abnormal and drugs with ingredients of cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate (396 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Genvoya:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Bone density abnormal:

Bone density abnormal (247 drugs)

Browse all the conditions that are associated with Bone density abnormal:

Bone density abnormal (252 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate (the active ingredients of Genvoya) and Genvoya (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.